The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in the brain.

Siemens Healthineers will leverage its regional network and healthcare technology expertise to support the adoption of Aiforia's pathology tools.

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

The new swab technology allows for non-invasive collection of patient samples without the need for liquids or complex devices.